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2
Conventional Therapy for Pancreatic Cancer

CANAVANINE ANALOGS AND THEIR USE
AS CHEMOTHERAPEUTIC AGENTS

Currently, surgery is the primary and only curative
therapy for pancreas cancer. HoWever, only 15—25% of

CROSS-REFERENCE TO RELATED
APPLICATIONS

tumors are resectable at the time of diagnosis9 and regret

tably only 10—20% of patients resected Will survive more
than tWo yearslo. With these less than satisfactory surgical
results, present day therapy has evolved in tWo directions:
palliation of symptoms and aggressive multimodality treat
ment regimes Which combine surgery With chemotherapy

This application is a continuation-in-part of application
Ser. No. 08/353,270, ?led Dec. 5, 1994 now US. Pat. No.

5,552,440 Which issued incorporated herein by reference in
its entirety.
10

TECHNICAL FIELD

The invention relates to a pharmaceutical composition
comprising canavanine analogs, and a method of treatment
of cancer, particularly pancreatic cancer, With canavanine

analogs.

and radiation treatment.

Palliative therapy has become a major thrust of current
treatment. Initial relief of symptoms has relied on surgery

With surgical bypass of gastric outlet obstruction11 and
operative bypass of biliary obstruction12. Subsequent symp
15

tomatic treatment has centered around endoscopic place
ment of biliary stents to bypass tumors blocking the biliary

tract13 and/or percutaneous placement of bypass conduits14.

Aggressive multimodality therapy combining chemo

BACKGROUND

therapy and radiation therapy With surgery has been the

L-Canavanine [L-2-amino-4-(guanidinooXy)butyric
acid], a nonprotein amino acid found in certain leguminous
plants37, is a structural analog of L-arginine in Which the
terminal methylene group is replaced by oxygen.
L-Canavanine, a substrate for arginyl-tRNA-synthetase, is

20

incorporated into neWly synthesiZed protein in place of
arginine to create structurally aberrant and dysfunctional
proteins38. Available evidence supports the contention that

25

an important biochemical basis for canavanine’s insecticidal
and antitumor activities is the formation of dysfunctional

canavanine-containing proteins.39>4O
More than 26,000 people die each year in our country
from pancreatic adenocarcinomal. Death is the inevitable
consequence to more than 90% of patients With this disease.

Effective radiotherapy needs to maXimiZe eXposure of the

affected tissues While sparing normal surrounding tissues.
Interstitial therapy, Where needles containing a radioactive
source are embedded in the tumor, has become a valuable
neW approach. In this Way, large doses of radiation can be
35

delivered locally While sparing the surrounding normal
structures17. Intraoperative radiotherapy, Where the beam is
placed directly onto the tumor during surgery While normal
structures are moved safely aWay from the beam, is another

specialiZed radiation technique. Again, this achieves effec
40

lymphoma and carcinoid; hoWever, 75—80% of the cases
involve adenocarcinomas of ductal origins. The only de?ni
tive risk factor in pancreatic cancer is cigarette smoking. A

tive irradiation of the tumor While limiting eXposure to

surrounding structures. Despite the obvious advantage of
approaches predicated upon local control of the irradiation,
patient survival is not signi?cantly improvedls’lg.

typical smoker accepts up to four times the risk of a

nonsmoker6.

A single, small randomiZed trial shoWed signi?cant ben
e?t from combined radiation and chemotherapy given tWo
years after operation16. While this study Was limited by an
inadequate number of patients, nonetheless there Was bene?t

to patients receiving multi-modality treatment.
30

It is the fourth most common cause of cancer death in men

and the ?fth most common for Women2. Overall, it is the
fourth most common carcinoma after those of the lung,
colon and breast3. The incidence of this disease is linear With
age to siXty but its occurrence increases markedly in the
seventh or eighth decade of life“. There are several different
histologies associated With cancer of the pancreas including
small cell cancer, cystadenocarcinoma, islet cell tumors,

response of choice When surgery alone Was not effective.
Radiation has been the cornerstone of therapy for unresec
table cancer of the pancreas and 5-?uorouracil (5-FU)
chemotherapy has been an important adduct to radiation
treatment in these patients15 . HoWever, despite these valiant
efforts, no patient survives ?ve years.

45

Located in the upper abdomen in the retroperitoneum, the
pancreas is associated intimately With many major structures

The foundation of chemotherapy for carcinoma of the
pancreas has employed 5-FU2O. Here too, the prognosis is
bleak; no better than 10—15% of patients treated With 5-FU
Will experience a signi?cant reduction in tumor siZe; overall

including the portal vein, stomach, duodenum, common bile

survival rates are not improved. The addition of other

duct and the superior mesenteric artery. As the tumor groWs,
the patient’s symptoms result from tumor in?ltration of

chemotherapeutic agents such as cis-platin or adriamycin

surrounding structure causing pain, nausea, vomiting,

this reason, attempts to augment the intrinsic activity of
5-FU have been undertaken. On one approach, 5-FU is

has not dramatically improved disease managementzo). For

Weight loss and jaundice. The latter condition presents
symptoms in no more than one half of the patients. Once
tumor in?ltration occurs other structures such as the portal

vein become affected and this precludes curative resection
ing of the pancreas.

55

replication by curtailing deoXyuridine monophosphate
anabolism to deoXythymidine.

Effective treatment of pancreas cancer must achieve tWo

dif?cult goals: control of the primary tumor mass, both
initially and subsequently, and treatment of the metastatic
tumor cells. As a result of its insidious onset, the diagnosis
of pancreas cancer is delayed frequently for several months.

converted to 4-?uorodeoXyuridine monophosphate
(FdUMP) Which binds covalently to thymidylate synthase
(EC 2.1.1.45). This competitive inhibitor disrupts DNA
Reduced folates such as leucovorin are a necessary cofac

tor for FdUMP binding to thymidylate synthase21. Cancer
60

cells depauperate in reduced folate are resistant to 5-FU

chemotherapy, but that resistance can be circumvented by

This delay has profound implications, since metastatic

providing eXogenous reduced folate22. While 5-FU plus

spread to the liver or lymph nodes has been observed at a

leucovorin relative to 5-FU alone has proven efficacious in
treating colon cancer, patients With pancreas cancer received

time of diagnosis in 60% of patients, and this factor dimin
ishes the prospect for long-term survival7. Also, there are no
knoWn speci?c markers of carcinoma of the pancreas and it

is asymptomatic in its early stages.

65

no bene?t by receiving these tWo drugs in combination23.
5-Fluorouracil can also be converted to 5-?uorouridine

monophosphate Which can be incorporated into mRNA

5,859,295
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thereby affecting protein translation. N-N- (phosphonacetyl)

and

—L-aspartic acid (PALA) inhibits the transformation of aspar
O

tic acid to orotidine monophosphate Which is converted
subsequently to uridine monophosphate. The use of PALA
provides a means of depleting essential uridine monophos

HOOC

NH;

>/\/

Formula 4

“
/NH2
C—N=C

\NHZ

phate. In the absence of uridine monophosphate, ?uorouri
O

dine monophosphate is incorporated preferentially into

Formula 5

mRNA Which promotes cell death. Preliminary data from

experiments employing high dose (2,600 mg/m2) 5-FU after

O

RrO
1O

R2

,'

R3

n

NH

\N%

2

NH;

pretreatment With PALA have been promising, as signi?cant
tumor reduction has been noted in 5 of 6 patients“.

HoWever, subsequent phase II data have been less positive25
With only one patient in 29 achieving any bene?t. While neW
experimental efforts in treating pancreas cancer have been
initiated, their limited success emphasiZes the need for
radically neW approaches in the management of this devas
tating disease. The present invention provides an additional
alternative for the treatment of cancers, particularly pancre

15

atic cancer, by providing for a pharmaceutical composition
comprising canavanine, and a method of treatment of cancer,

particularly pancreatic cancer With canavanine.
NR3R4

Formula 6

25

DISCLOSURE OF THE INVENTION

a

The present invention provides a method of treating
pancreatic cancer by administering a pharmaceutically
effective amount of a composition comprising canavanine
analogs to a patient With pancreatic cancer.
The canavanine analog compound may have a formula
selected from:
Formula 1 35

H
N

[ >®—SCH2H5I9
N
H

R1 is selected from SCH2H5I9;
H
N

Formula 2

[ \>—R2

45

N
H

R2= SC2H5
OCZHS;
/ R3

R4\ 00c
HN

>/\/

The invention also provides a pharmaceutical composi

F ormu l a 3

tion comprising a pharmaceutically effective amount of a

N
O—N=C/

\R5

composition comprising canavanine analogs.

NHZ

In an alternative embodiment the invention provides a
55

log and 5-?uorouracil.

Wherein

In still another embodiment, the invention provides a

pharmaceutical composition comprising canavanine and a
compound selected from the group consisting of (S)-2

R3 is H2; —(CH3)2; or H-Boc
R4 is —CH2CH3; or —CH3
R5 is H; H-Boc; or

—CO

pharmaceutical composition comprising a canavanine ana

aminoethyl-L-cysteine, L-2-aZetidine carboXylic acid,

L-selenomethionine, L-3-[N-hydroXy-4-oXypyridyl]—2
aminopropionic acid and mixtures thereof.
The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

;

65

folloWing detailed description and ?gures, Wherein only the
preferred embodiments of the invention are shoWn and

described, simply by Way of illustration of the best mode of

5,859,295
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6

carrying out the invention. As is readily recognized, the
invention is capable of modi?cations Within the skill of the
relevant art Without departing from the spirit and scope of

chemical defense, Where it functions as a barrier against a

Wide array of insects and other pests28>29.
Biochernical Basis for Canavanine’s Antirnetabolic Proper

the invention.

ties
Studies With larvae of the tobacco horn Worrn, Manduca
sexta, reveal that canavanine is an effective substrate for

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1. The effect of canavanine enantiorners and chain
length rnodi?cations on MIA-PaCa-2 cell viability. MIA
PaCa-2 cells Were treated With the indicated concentration

of: L-Canavanine (1, —O—), L-Hornocanavanine (2, —I—),
D-Canavanine (3, G), or D-2-Arnino-3-(guanidinooXy)

arginyl-tRNA synthetase. This canavanine-sensitive insect
replaces on average at least one of three arginyl residues
10

With canavanine in the de novo synthesiZed proteins of the
hernolyrnph and body wall30 .
Vitellin, an essential egg protein, is constructed by the

gravid rnigratory locust, Locusta migratoria rnigratorioides

propionic acid (4, —A—) See teXt for additional experimental

[Orthoplera] from amino acids released by degradation of

details.
FIG. 2. The effect of structural rnodi?cation of the guani
dinooXy group of L-Canavanine on MIA-PaCa-2 cell viabil
ity. MIA-Pa-Ca cells Were treated With the indicated con

vitellogenin‘. Administration of canavanine to the female
locust produces a canavanyl vitellogenin in Which 18 of the

15

nearly 200 arginine residues are replaced by canavanine31;
thus, canavanine occurs about once every 225 amino acids.

In spite of this paucity in canavanine content, it elicits a
profound alteration in vitellogenin structure best observed

centration of: L-Canavanine (1, -O-), L-2-Arnino-4-(1
irnidaZolidenearninooXy) butanoic acid (8, —I-), or L-2

by electrophoretic analysis.

arnino-4-[assyrn-NG, NG-dirnethyl(guanidinooXy)] butanoic

Other chemical, physical, biochemical, and immunologi

acid (9,

cal tests con?rrn the dramatic change in the three dirnen
sional conforrnation resulting from canavanine assirnilation

FIG. 3. The effect of L-canavanine esters on MIA-PaCa-2

into this protein31.

cell viability. MIA-PaCa-2 cells Were treated With the indi

cated concentration of: L-Canavanine (1, -O-),
L-Canavanine Methyl Ester 2HCl (10, 15-), L-Canavanine
Ethyl Ester 2HCl (11,€-), L-Canavanine Isopropyl Ester
2HCl (12, -El-), L-Canavanine n-Propyl Ester 2HCl (13,
—I-), L-Canavanine n-Butyl Ester 2HCl (14, -Q), or

25

a group of antibacterial proteins knoWn trivially as the
diptericins. If canavanine is included at the time of mechani

cal injury, it is incorporated into neWly produced dip
tericins32. Analysis of the diptericin activity of arginine- or
canavanine-treated larvae reveals a nearly total loss of

L-Canavanaine n-Octyl Ester 2HCl (15,
See teXt for
additional experimental details.
FIG. 4. Comparison of IC5O values of L-canavanine and
some of its esters.

detectable biological activity for 3 of the 4 protective

proteins-only diptericin A displays biological activity. Thus,
canavanine incorporation into these protective proteins in
35

place of arginine severely curtails their biological activity.
Manduca sexta larvae respond to injected fragments of
the cell Wall of Micrococcus lutea by producing lysoZyrne
(EC 3.2.1.17), a protein Which cleaves the rnucopolysaccha

O

O

In response to microbial infection or mechanical injury,

larvae of the rneat-eating ?y, Phormia terranovae, generate

NH;

ride framework of the cell Wall. Administration of 1 mg

canavanine g-1 fresh larval Weight at the time of bacterial
challenge generates canavanyl lysoZyrne With a ratio of

canavanine to arginine of 1:38:02 (33). Canavanyl
lysoZyrne exhibits a 50% loss of catalytic activity33. These
45

insectan studies support the contention that the antirneta
bolic effects of canavanine re?ect its incorporation into

neWly synthesiZed proteins Which alter essential conforma
tion and produces dysfunctional proteins.
Canavanine may be produced by isolating the amino acid
from jack beans by the method of KitagaWa, Tokiyarna, J.

Biochern., (Tokyo) 11, 265 (1929) incorporated herein by
reference in its entirety. See also Nyberg et al., J. Am. Chem.
Soc., 79, 1222 (1957); Frankel et al., J. Am Chem. Soc.,
3127 (1963); and Yarnada et al., Agr., Biol. Chern., 37, 2201

comprising a canavanine analog, and a method of treatment

(1973) for additional methods of synthesis of canavanine,
also incorporated herein by reference.
Evaluation of Canavanine’s Antineoplastic Activity
Canavanine’s ability to disrupt the groWth of rapidly

of cancer, particularly pancreatic cancer, With canavanine. A
depiction of the basic canavanine rnolecule appears beloW.

dividing and groWing larval cells led to whole animal studies
of its antineoplastic activity. The inventors found that cana

In addition to the amino acids Which are the building

vanine may be incorporated into key protein(s) unique to the

blocks of proteins, living systems also produce about 750

cancer cell and that these structurally aberrant proteins,
critical to the groWth and proliferation of the cancer cell,

DESCRIPTION OF THE INVENTION
55

The invention provides a pharmaceutical composition

nonprotein arnino acids26. These compounds possess a rich
structural diversity and often elicit deleterious biological

may be dysfunctional.

effects in viruses and all living systems”, L-Canavanine, the

L-2-arnino-4-(guanidinooXy) butyric acid structural analog
of L-arginine, is such a higher plant toXicant. Produced and

stored by legurninous plants, canavanine is part of their

65

EXAMPLE 1

Employing a solid rat colonic carcinoma in Fischer F433
rats, it was demonstrated that canavanine analogs of the

5,859,295
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7
invention possesses appreciable antineoplastic activity. For

A chemotherapeutic strategy predicated upon controlling

example, administration of a canavanine analog at a 3.0 g/kg
dosing regimen for 5 consecutive days results in a 22% loss
in tumor volume, While 9 days of daily dosing elicits a 60%
diminution of the tumor“.
HoWever, the canavanine analogs are cumulatively toxic

cancer cell groWth through the formation of structurally

aberrant, dysfunctional proteins has been developed. Such
macromolecules deny the cancer cell essential metabolites,
undermine regulatory and other cellular control elements

and pervasively disrupt critical cellular groWth-related pro

and can result in a Weight loss of 19% in animals dosed With

3.0 g/kg canavanine for 5 days“. Additional experimenta
tion established unequivocally that the observed body
Weight loss is not responsible for the canavanine analog

compounds antitumor effects“).

10

ment of neW derivatives for use as chemotherapeutic agents.

Most importantly, the canavanine analogs’ mode of action is

EXAMPLE 2

Initial experimental efforts have been extended to deter
mine if canavanine analog ef?cacy as an anticancer agent is
increased in combination With 5-?uorouracil (5-FU). Pro
viding a canavanine analog at 1.0 g/kg or 2.0 g/kg daily for

cesses. Current treatment practices have not enjoyed sub
stantial success and a radical neW approach is justi?ed. The
approach of the invention is one With a strong biochemical
foundation that provides a sound rationale for the develop
not directed at DNA replication, events that occur prior to
transcription of the message, nor at message translation.

15

The present strategy for developing an effective chemo
therapeutic agent does not focus on nucleic acid metabolism
but rather at the level of protein function.

5 consecutive days With 5-FU signi?cantly increases the

Evaluation of Drug Efficacy

antitumor activity of either drug alone (see FIG. 4). Body
Weight loss experienced by canavanine-treated animals

A number of cell lines derived from pancreatic ductal
adenocarcinoma have been established, including CFPAC-1

increases in those animals given both drugs. These studies

improving canavanine analogs intrinsic ef?cacy.

(ATCC CRL 1918), PANC-1 (ATCC CRL 1469), MIA
PaCa-1, and MIA-PaCa-2 (ATCC CRL 1420). MIA-PaCa2
is highly tumorigenic, has lost the ability to be groWth

In order to improve canavanine analogs potential as
chemotherapeutic agents, a number of canavanine analogs

Which is derived from a primary tumor line, is the faster

20

evidence that combination therapy offers a viable means of

Were evaluated for enhanced antitumor ef?cacy and dimin

ished groWth-inhibiting activity.

regulated, and is derived from metastatic cells. CFPAC-1,
25

Type Culture Collection, 12301 ParklaWn Drive, Rockville,

EnZyme activity studies conducted, reveal a number of
other nonprotein amino acids Whose assimilation into pro

Md., USA, insures an effective means for initial screening of

neWly synthesiZed derivatives both alone and in combina

teins disrupts normal catalytic activity. Some natural prod
ucts such a (S) -2-aminoethyl-L-cysteine, L-2-aZetidine car

30

boxylic acid, L-selenomethionine, and L-3-[N-hydroxy-4
oxypyridyl]-2-aminopropionic acid or mixtures thereof are

not only very active but also interact With canavanine to

signi?cantly amplify canavanine-mediated disruption of

protein function”.

35

Thus, there are a number of nonprotein amino acids
besides canavanine able to substitute for their protein amino

40

The ability to assault the local cancer cell and even its
metastatic offspring simultaneously With an array of non
protein amino acid derivatives offers a Weapon of consid
45

50

amount found in liver, muscle or brain samples. The ef?cient

vented tumor groWth during 5 or 9 consecutive treatment

days. In fact, the ?nal fresh tumor Weight Was typically 10%
less than the Weight of the initial tumor34.
To enhance canavanine’s antineoplastic activity, it Was
tested in combination With 5-FU. Providing canavanine at
1.0 g/kg or 2.0 g/kg daily for 5 consecutive days With 5-FU

signi?cantly increased the antitumor activity of either drug
alone. This Whole animal study Was of considerable impor
tance because it demonstrated that combination therapy

incorporation of radiolabeled canavanine into pancreatic
proteins coupled With its demonstrated ability to create
dysfunctional proteins prompted evaluation not only of
canavanine but more importantly its derivatives as chemo

Rat
The marked antitumor effect of canavanine analogs Was
demonstrated initially by our research group in studies on a
solid, colonic carcinoma in male Fischer 344 rats. Admin

istration of 3 g/kg canavanine analogs reproducibly pre

organs of the rat disclosed the highest radiolabeling in

pancreatic proteins“. These proteins had 10 times the

employed presently in human chemotherapy. The most
promising candidates are employed in Whole animal evalu
ation involving nude mice.
This invention permits an effective transition from labo
ratory ?ndings and evaluations to their bene?cial employ
ment in alleviating the human suffering associated With this
dreadful disease.

Antitumor Effect of Canavanine analogs in the Male Fischer

therapeutic drugs.

erable potential value.
Canavanine’s Ef?cacy against Pancreatic Tumor
Analysis of L-[guanidinoxy-14C] canavanine and other
canavanine analog uptake into the protein of the major

tion With other developed compounds as Well as With drugs

EXAMPLE 3

acid counterpart to generate dysfunctional proteins. These
natural products often possess signi?cant antitumor poten
tial alone, in combination With canavanine, and With other

groWing cell line and is preferable for Whole animal studies.
The availability of each of these lines from the American

offers a viable mean of improving canavanine’s intrinsic
55

therapeutic agents for human pancreas cancer.
Abasic understanding of the biochemical basis for cana
vanine’s antimetabolic properties has emerged over the past

ef?cacy and supports the contention that canavanine and its
derivatives in conjunction With 5-FU may offer an effective

chemotherapeutic strategy. Alternatively, canavanine
therapy may be combined With radiotherapy.

?ve years and these efforts have permitted development of

thetic efforts, detailed herein, hold the promise of providing
drugs With markedly enhanced ef?cacy and permit their

EXAMPLE 4
The Effect of Canavanine on MIA-PaCa-I Cells
Work has been performed to evaluate the effect of cana
vanine on MIA-PaCa-1 cells. Cell survival Was determined

administration at signi?cantly loWer dose levels than those

by the ability of viable cells groWn on Dulbecco’s modi?ed

a sound rationale for derivative synthesis. Chemical syn

60

required by canavanine. It has been unequivocally estab
lished that a 1 g kg'1 dose of canavanine has no adverse
effect on body Weight nor on other discernible parameters of
the rat.

medium to reduce tetraZolium dye to a colored formaZan
65

product. The experiment depicted in FIG. 4 dramatically
discloses the potent ef?cacy of canavanine against these
cells.

5,859,295
10
That the antitumor potential of canavanine analogs is
related directly to the competing arginine concentration.
This ?nding is of great importance because it reveals that
canavanine is functioning as an effective arginine antagonist.

dinooxy functional group Was considered to be an effective

alteration Which might result in an increase in af?nity for the

arginyl-tRNA synthetase active site. Similarly, the chain
shortened analog, in Which only one methylene group is

This point is seminal to our contention that the antitumor

present in the molecule Was evaluated. Second, it is reason
able to contend that the antitumor activity of canavanine is

effect of canavanine is related to its competition With argi

nine for arginyl-tRNA synthetase.

stereospeci?c for the L-isomer, since arginyl-tRNA syn
thetase Would undoubtedly recogniZe only the L-enantiomer

EXAMPLE 5

of arginine as a substrate. Hence, the biological activity of

The Antineoplastic Effect of Canavanine in the Nude Mouse
Experiments With athymic nude mice Were conducted
With 6 treated and control mice. The palpable CFPAC-1
derived tumors greW sloWly but after 28 days appreciable
tumor groWth had occurred in all experimental animals

(FIG. 6A). By contrast, the CPFAC-1-derived tumors exhib
ited little groWth in canavanine-treated animals (FIG. 6B). In

the D-enantiomer of canavanine Was pursued to determine if

it exhibited MIA-PaCa-2 cell groWth-inhibitory activity and

15

2 of the 7 experimental animals, a precipitous decline in
tumor volume Was observed during the ?rst treatment Week.

to compare the activity of this stereoisomeric form With that
of its naturally occurring antipode. It Was believed that
D-canavanine Would not be an arginyl-tRNA synthetase
substrate; thus, any adverse effects noted With D-canavanine
could not result directly from its incorporation into neWly
synthesiZed protein. In this respect, the D-enantiomer offers

These exciting experimental results add further support to

a means of evaluating canavanine’s activity divorced from

the fact that canavanine and its derivatives possess consid
erable potential for the treatment of human pancreatic car
cinoma.

its role in protein synthesis. Third, ionic and hydrogen
bonding interactions of the guanidino group of arginine With
neighboring amino acid residues are crucial for establishing
the three-dimensional structure of a protein; replacement of

A number of structural analogs of L-canavanine [L-2

amino-4-(guanidinooxy) butyric acid] the 6-oxa analog of

this moiety With the guanidinooxy moiety of canavanine

L-arginine, have been synthesiZed and their groWth

results in the formation of aberrant and dysfunctional

inhibitory effects evaluated in cultured MIA-PaCa-2 pan

25

creatic carcinoma cells by the 3- (4.5-dimethylthiaZol-2-yl)
-2,5-diphenyltetraZolium bromide (MTT) assay. The results

protein.3o’44 Thus, analogs in Which the guanidinooxy group
has been further modi?ed appears to cause a greater delete

rious effect on the tertiary/quatenary structure of arginyl

indicate that D-canavanine and analogs in Which the carbon

containing proteins than does canavanine. Thus, the effect of

chain-length and/or terminal guanidinooxy functional group
has been modi?ed elicit less groWth inhibitory activity than

structural alteration of the terminal guanidinooxy group of
L-canavanine Was also evaluated.

L-canavanine. On the other hand, several ester derivatives of

Finally, the methyl, ethyl, isopropyl, n-propyl, n-butyl,

L-canavanine have markedly enhanced groWth inhibitory

and n-octyl esters of L-canavanine exhibit greater lipophi
licity than canavanine and appear to possess improved cell
membrane penetration properties. These compounds can
constitute prodrug candidate forms of L-canavanine, and can
be attacked by cytosolic esterases to generate the parent

activity compared to L-canavanine. Thus, esteri?cation con
stitutes an effective structural modi?cation Which signi?

cantly ampli?es the groWth inhibitory properties of the
parent compound against MIA-PaCa-2 cells.

35

compound.
Chemistry
L-2-Amino-5-(guanidinooxy)pentanoic acid (L-HMCAV,

L-Canavanine at 3.0 g/kg daily dose for 5 days elicits
signi?cant inhibition of rat colon carcinoma, causing a 22%
loss in tumor volume. A 60% loss in tumor volume is

observed for a similar 9-day treatment period. HoWever,

homocanavanine; 2) and D-canavanine (D-CAV); 3) Were
synthesiZed from D-methionine and L-glutamic acid

during this treatment, L-canavanine exhibits signi?cant
cumulative toxicity in the form of Weight loss of 19%36>41.

5 -methyl ester respectively, as reported in Rosenthal et al.45 .

Additional experiments have established that the reduction
in tumor volume is not related to the observed body Weight

loss. Preliminary studies in nude mice carrying pancreatic

The shortened chain-length analog of D-canavanine, D-2
amino-3-(guanidinooxy)propionic acid (D-GOA, 4) Was
45

ductal adenocarcinoma (CFPAC-1), shoW a signi?cant
decrease in ?nal tumor volume after dosing animals With
palpable tumors With 4 g/4 kg canavanine for 28 consecutive

synthesiZed via ring opening of D-cycloserine (5) to give
D-2-amino-3-(aminooxy)propionic acid (6), folloWed by
Zinc-mediated guanidination With cyanamide (Scheme 1).
Structural alteration of the guanidinooxy group of

days. Canavanine proved even more effective When it Was
provided on a comparable dosing schedule Which com

canavanine, as in the ethylene (L-ETCAV, 8) or dimethyl
analog (L-DMCAV, 9), Was achieved by reacting the copper
salt of L-canaline (7) With 2-ethoxyimidaZoline or

menced 1 day after tumor cell implantation42. These studies
reveal that canavanine is an effective chemotherapeutic
agent for the treatment of pancreatic cancer.

dimethylcyanamide, respectively (Scheme 2).

On-going investigation of canavanine’s antineoplastic

L-canavanine (L-CAV, 1) With the appropriate anhydrous

activity demonstrates the value of developing canavanine
analogs With diminished toxicity and enhanced potency.
This application also describes synthetic methods for pre

L-Canavanine esters Were produced by heating
55

DETAILED DESCRIPTION OF THE FIGURES

As shoWn in FIG. 1, cell viability assays indicate that
alteration of the number of methylene groups betWeen the
amino [3-carbon and the guanidinooxy group does not
enhance the groWth-inhibitory effects of the parent com
pound in cultured MIA-PaCa-2 cells. Decreasing the num
ber of methylene groups from 2 to 1, in addition to inverting

paring a number of L-canavanine derivatives and evaluates

their groWth-inhibitory potency against cultured MIA
PaCa-2 cells.
Modi?cations of the canavanine molecule are based on

the folloWing considerations. First, since x-ray crystallo
graphic studies have revealed that the interatomic distance
betWeen the [3-carbon and the carbon of the guanidino group
of canavanine is someWhat shorter than that in the arginine
molecule43, an insertion of an extra methylene group into the

canavanine molecule While retaining the important guani

alcohol saturated With HCl gas.

the stereochemistry at C-2 (D-GOA, 4) results in almost
65

complete loss of groWth-inhibitory activity When compared
to that of L-canavanine. An increase in methylene group
number from tWo to three (L-homocanavanine, L-HMCAV,

5,859,295
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2) affords a compound that exhibits only Weak growth

Cell viability Was assessed by the metabolic 3-(4,5

dimethylthiaZol-2-yl)-2,5-diphenyltetraZolium bromide
(MTT) assay previously described by Kissane5 With minor

inhibitory properties. These results are consistent With the
belief that chain shortening produces an analog less likely to
be recognized as a substrate for arginyl-tRNA synthetase
and Would therefore not be ef?ciently incorporated into
protein. The results obtained for the chain-lengthened ana
log suggest that a crucial intra-atomic distance is required
betWeen the amino acid functionality and the terminal

modi?cations. The metabolic MTT assay measured the
ability of viable cells to reduce a tetraZolium dye to a
formaZan chromogen, Which could be measured at 630 nm.

MIA-PaCa-2 cells, maintained in exponential groWth for up

guanidinooxy moiety for recognition by the amino acyl
synthetase enZyme.
The D-isomer of canavanine (3) exhibits a Weak but

10

signi?cant decrease in groWth-inhibitory activity against

performed 48 h. after addition of the drug. Viability Was
calculated as the percentage of the drug-free control cell

MIA-PaCa-2 cells, and Was similar in potency to the chain

elongated L-homocanavanine

Thus, the L-isomer of

population 1 SEM.

canavanine is signi?cantly more effective in the groWth

inhibitory activity than the D-isomer, Which may re?ect the

to 72 hr. Were plated at 5><103 cells/Well in a 96-Well plate.
The cells Were alloWed to groW for 24 h. prior to drug
addition. Four replicate Wells Were used for the drug-free
control and for each drug concentration. MTT assays Were

15

different abilities of these enantiomers to be incorporated

Silica gel plates (2.5><7.5 cm, 250 pm layer, ?uorescent at
254 nm) Were purchased from Diamond Whatman

into arginyl-containing protein. The groWth inhibiting activ

International, Ltd. (Clifton, N.J

ity of D-canavanine also suggests that D-canavanine’s anti
metabolic properties result from factors other than aberrant,

separations Were carried out With silica gel (200—400 mesh,

canavanyl protein formation.

60
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Structural modi?cation of the guanidinooxy functional

from Fisher/Aldrich (Milwaukee, Wis.). Chemicals

and solvents Were secured from Fisher/Aldrich Chemical
Co. Melting points Were recorded on a Fisher-Johns melting

point apparatus, and are uncorrected. 1H-NMR and 13C

group (8 and 9) affords compounds With signi?cantly
reduced groWth inhibitory activity against cultured MIA

NMR spectra Were carried out on a Varian VXR-300 MHZ

spectrometer (Palo Alto, Calif.); spectra Were run at 21° C.

PaCa-2 cells, as compared to L-canavanine (FIG. 2). The

assym-NG, NG-dimethyl analog (9) exhibits Weak groWth

Column chromatographic

25

inhibitory properties and is slightly less active than the NG,

in either CDCl3, DMSO-d6, or D20 using tetraethyl silance
(TMS) or the sodium salt of 3-(trimethyulsilyl) propionic

NG-ethylene analog

2,2,3,3-d4 acid (TSP) as an internal standard. Elemental

inhibitory activity.

Ga.), [ot]D23 values Were observed at 589 nm and determined

The results suggest that an intact
guanidinooxy group is required for maximum groWth

The methyl, ethyl, and n-propyl esters (10, 11, 13) of
canavanine exhibit slightly improved groWth-inhibitory

analyses Were performed by Atlantic Microlabs (Norcross,
30

activities in MIA-PaCa-2 cells With IC5O values of 0.79,

0.67, and 0.62 mM, respectively, When compared to
L-canavanine (IC5O value=1.33 mM, FIG. 3 and 4).
Interestingly, the n-butyl and n-octyl esters of
L-canavanaine (14, 15) elicit the most signi?cant increase in
groWth inhibitory activity With IC5O values of at 0.32 and
0.24 mM, respectively. This improved potency may be due
to the increased lipophilicity and enhanced membrane

penetrational properties of the ester analogs.
When compared to L-canavanine, the isopropyl ester (12),
Whose IC5O is 1.27 mM, also shoWs a slight increase in
groWth inhibitory activity up to a concentration of 1.5 mM;
at higher concentrations, this ester Was less active than
L-canavanine. Compared to the other esters that Were

evaluated, the isopropyl ester is more sterically hindered
around the carbonyl moiety of the ester functionality and
therefore more resistant to enZymatic hydrolysis, this factor
appears to account for its loWer overall activity. Since
ZWitterion formation is not possible for esters of amino
acids, these esters shoWed enhanced lipophilicity and better
transport characteristics than the parent amino acid. This
property may provide a basis for the development of effec
tive prodrug analogs of L-canavanine that possess greater

bioavailability.

EXAMPLE 7
35

D-2-Amino-3-(aminooxy)propionic acid

dihydrochloride (6)
D-Cycloserine (5, 408 mg. 4 mmol) Was dissolved in 2N
HCl (20 mL); the resulting solution Was kept at 60° C. for
6 h. After cooling to 00 C., the solution Was adjusted to pH

40

4.5 With 15% (W/v) NaOH and Was applied to a 25 cm3
DoWex 50x8 (H+) column. The resin Was Washed With

deioniZed Water (500 mL) folloWed by 5N NH 4OH (80 mL).
The column effluent Was concentrated by rotary evaporation
in vacuo to give 6 (480 mg, 99% yield) as a colorless solid,
45

mp. 167.0°—169.5° C.; [a]D23=+24.5° (c=2.15, H2O);
1H-NMR (D20); 64.79 (dd, J=11.0, 5.2 HZ, 1H, 3-CH2a)
4.62 (dd, J=11.0, 3.0 HZ, 1H, 3-CH2b), 4.55 (dd, J=5.2, 3.0
HZ, 1H, 2-CH) ppm; 13C-NMR (D20): 6170.95 (C-1), 74.19
(C-3), 54.41 (C-2) ppm; Anal (C3H1OCl2N2O3) C, H, N, Cl.

50

EXAMPLE 8

D-2-Amino-3 (guanidinooxy)propionic acid (4)
55

EXAMPLE 6
Human Pancreatic Carcinoma Cell Culture and Cell Viabil

Copper oxide (750 mg) Was added to a solution of 6 (480
mg, 4 mmol) in distilled Water (5 mL). The mixture Was
heated for 5 min at 100° C., for 2 h. at 50° C., and for 24 h.
at 23° C. The unreacted CuO Was ?ltered, and the ?ltrate
Was adjusted to pH 9.2 With 1N NaOH. This solution Was

ity Assays
Human pancreatic carcinoma cells (MIA-PaCa-2) Were

on a Perkin-Elmer 241 polarimeter. MS data Were carried
out on a Kratos concept 1H MS50 spectrometer.

60

then added to a solution of cyanamide (190 mg, 4.60 mmol)
and ZnCl2 (705 mg, 5.2 mmol) dissolved in a minimum

purchased from the American Type Cell Collection (ATCC).

amount of Water. The resulting mixture Was stirred at 50° C.

The cells Were groWn in Dulbecco’s Modi?ed Eagle’s

for 3 days. The reaction Was terminated by bubbling hydro
gen sul?de through the reaction mixture for 10 min; the

Medium (DMEM) containing 10% (v/v) fetal calf serum.
Cell viability assays Were performed With MIA-PaCa-2
cells in culture at the folloWing drug concentrations: 0.16,
0.31, 0.62, 1.25, 2.5, 5.0, and 10.0 mM. The drugs Were
dissolved into and diluted With DMEM.

65

resulting precipitate Was ?ltered. The ?ltrate Was evaporated
to dryness by rotary evaporation in vacuo to give 300 mg of
crude product (45% yield). Part of this product Was then
applied to a cellulose column (15x1 cm) and eluted With

5,859,295
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ethanol: 0.2N NH4OH (70:30). The last eluting fraction Was
evaporated to dryness to give pure 4 as a glassy solid;

EXAMPLE 12

[ot]D23=+7.5° (c=1.35, H2O); 1H-NMR (D20): 64.28 (dd,

Methyl L-2-amino-4-guanidinooxybutanoate (10)

J=6.0, 3.6 HZ, 1H, 2-CH), 4.14 (dd, J=11.0, 3.6 HZ, 1H,
3-CH2a), 4.08 (dd, J=11.0, 6.0 HZ, 1H, 3-CH2b) ppm;
13C-NMR (D20): 6177.14 (C-1), 159.42 (C=N) 75.63
(C-3), 58.91 (C-2) ppm.

(71% yield); [a]D23=+19.5° (c=0.45, H2O); 1H-NMR

Compound 10 Was obtained as a White hygroscopic solid

EXAMPLE 9

L-2-Amino -4(1 -imidaZolideneaminooxy)butanoic

10

acid (8)
The ethylene analog of canavanine 8, Was obtained by
treatment of the copper salt of L-canaline (1 mmol, 7),
prepared as described for 4, With 2-ethoxyimidaZoline (240
mg, 1.8 mmol) in Water (5 mL) at 45° C. for 4 days. After
adjusting the solution to pH 5.0 With 1N NaOH, hydrogen
sul?de Was bubbled through for 5 min. The acidic reaction
mixture Was ?ltered and the ?ltrate adjusted to pH 3.4 With
1N NaOH. This solution Was applied to a 25 cm3 column of
DoWex 50><8 (NH 4") and the resin Was Washed With distilled

EXAMPLE 13

Compound 11 Was obtained as a White hygroscopic solid

(75% yield); [a]D23=+18.3° (c=0.52, H2O); 1H-NMR
20

ammonia Wash Was evaporated to dryness by rotary evapo
ration in vacuo, and the resulting residue Was puri?ed by

30
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L-2-Amino-4-[assym-NG, NG-dimethyl
(guanidinooxy)] butanoic acid (9)

ppm;

Anal.

Compound 12 Was secured as a White hygroscopic solid

(DMSO-d6): 69.00 (br s, 3H, NH3+), 7.84 (s, 5H, C(N
H2)(NH3+)’ 4.98 (sept, J=6.5 HZ, 1H OCH), 4.06 (t, J=6.0
HZ, 2-CH), 3.90—4.00 (m, 2H, 4-CH2), 2.10—2.25 (m, 2H,
3-CH2), 1.22 (d, J=6.0 HZ, 6H, 2><CH3) ppm; 13C-NMR
(DMSO-d6): 6168.58 (C-1), 158.59 (C=N), 72.03 (C-4),
69.90 (QH(CH3)2), 49.17 (C-2), 28.40 (C-3), 21.41, 21.32
(2><CH3) ppm; Anal. (C8H2OCl2N4O317 H2O) C, H, N, Cl.
EXAMPLE 15

40

solid utiliZing the procedure described for the preparation of

n-Propyl L-2-amino-4-guanidinooxybutanoate (13)

8, but using dimethylcyanamide in place of

Compound 13 Was obtained as a White hygroscopic solid

(96%); [a]D23=+28.7° (c=0.48, H2O); 1H-NMR (DMSO
45

d6): 68.20—9.20 (br s, 3H, NH3+), 7.80 (s, 5H, C(NH2)N
H3’), 4.08—4.22 (m, 2H, OCH2) 3.94—4.04 (t, 1H, 2-CH),
3.81 (2H, 4CH2), 2.08—2.32 (m, 2H, 3-CH2), 1.58—1.72 (m,
2H, OCHZCHZ), 0.88—0.96 (t, 3H, CH3) ppm; 13C-NMR
(DMSO-d6): 6169.09 (C-1), 158.36 (C=N), 71.95 (C-4),

50

67.22 (CHZO), 49.05 (C-2), 28.30 (C-3), 21.24 (
QHZCHZO), 10.11 (CH3) ppm; Anal. (C8H20Cl2N4O311
H2O.0.16 C3H7OH) C, H, N, Cl.

72.26 (C-4), 55.39 (C-2), 39.49 (2><CH3), 32.73 (C-3) ppm;
Anal. (C7H16N4O3.0.25H2O) C,H,N.

L-Canavanine Esters

The methyl, ethyl, isopropyl and n-propyl esters of cana
vanine (10—13) Were prepared by heating a solution of

L-canavanine (1, 1 mmol) in the appropriate anhydrous

(QHBCHZ)

(54% yield); [a]D23=+16.1° (c=0.54, H2O); 1H-NMR

EXAMPLE 10

EXAMPLE 11

13.99

Isopropyl L-2-amino-4-guanidinooxybutanoate (12)

calcd. for C7H14N4O3 203.1144 (MH+), found 203.1128.

2-ethoxyimidaZoline, m.p. 175.0°—177.0° (dec.); [a1D23=+
4.6° (c=1.6, H2O); 1H-NMR (D20): 63.98 (t, J=6.0 HZ, 2H,
4-CH2), 3.82 (t, J=6.0 HZ, 1H, 2-CH), 2.82 (s, 6H, 2><CH3)
ppm; 13C-NMR (D20): 6177.90 (C-1), 162.80 (C=N),

(C-3),

(C7H18Cl2N4O3.0.8 H2O. 0.12 CZHSOH) C, H, N, Cl.
EXAMPLE 14

[a]D23=+9.6° (c=2.4, H2O); 1H-NMR (D20): 64.08—4.17

Compound 9 (71% yield) Was obtained as a colorless

(DMSO-d6): 69.00 (br s, 3H, NH3+), 7.83 (s, 5H, C(N
HQNHJ), 4.18(q, J=6.5 HZ, 2H OCH2CH3), 4.10 (t, J=6.5
HZ, 1H, 2-CH), 3.85—4.00 (m, 2H, 4-CH2), 2.10—2.30 (m,
2H, 3-CH2) ppm; 13C-NMR (DMSO-d6): 6169.12 (C-1),
158.63 (C=N), 72.11 (C-4), 62.00 (QHZOOC), 49.17 (C-2),
28.42

25

combined and the solvent Was removed by rotary evapora
tion in vacuo to give pure 8 (29 mg, 16%) as a glassy solid;

(m, 2H, 4-CH2), 3.90 (t, J=6.0 HZ, 1H, 2-CH), 3.80 (s, 4H,
NCHZCHZN), 2.27 (dt, J=6.0 HZ, 2H, 3-CH2) ppm; 13C
NMR (CDCl3): 6176.66 (C-1), 164.09 (C=N), 75.72 (C-4),
54.99 ((3-2), 45.75 (ZXNCHQ), 3151 ((3-3) ppm; HRFABMS

Ethyl L-2-amino-4-guanidinooxybutanoate (11)

15

Water (500 mL) folloWed by 0.2N NH4OH (400 mL). The
cellulose column chromatography (25 x1 cm) by elution With
n-BuOH:AcOH:H2O (4:1:1). Fractions containing 8 Were

(DMSO-d6): 68.90 (br s, 3H, NH3+), 7.80 (s, 5H, C(N
HQNHJ), 4.10 (br s, 1H, 2-CH), 3.80—4.00 (m, 2H, 4-CH2),
3.70 (s, 3H, OCH3), 2.00—2.30 (m, 2H, 3-CH2) ppm; 13C
NMR (DMSO-d6): 6169.29 (C-1), 158.39 (C=N), 71.87
(C-4), 52.90 (CH3), 48.88 (C-2), 28.14 (C-3) ppm; Anal.
(C6H16Cl2N4O3.1 H2O.0.1 CH3OH) C, H, N, Cl.

EXAMPLE 16
55

alcohol (6 mL) saturated With dry HCl at 80° C. for 1 h. The

n-Butyl L-2-amino-4-guanidinooxybutanoate (14)

reaction mixture Was ?ltered and the ?ltrate removed by
rotary evaporation in vacuo to give a clear, gummy residue.

(91% yield); [a]D23=+16.7° (c=0.88, H2O); 1H-NMR

Compound 14 Was obtained as a White hygroscopic solid

The residue Was triturated With anhydrous ether (2 mL) and
the solvent decanted off. The resulting solid Was then dried

60

under high vacuum (0.5 mm Hg). The n-butyl and n-octyl
esters of canavanine (14,15) Were similarly prepared With
the folloWing modi?cations: the heating time Was increased
to 3 h. in 17% HCl/anhydrous 1-butanol (W/W) and 24 h. in

11% HCl/anhydrous 1-octanol (W/W), respectively. The
method for preparing the octyl ester of canavanine is
described in detail in the experimental section.
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(DMSO-d6): 68.20—9.20 (br s, 3H, NH3+), 7.80 (s, 5H, C(N
H2)NH3+), 4.18 (m,2H,(OCH2), 4.00 (t, 1H, 2-CH), 3.35
(t,2H, 4-CH2, overlap With Water peak), 2.08—2.28 (m, 2H,
3-CH2), 1.54—1.64 (m, 2H, OCHZCHZ) 1.26—1.44 (m, 2H,
OCHZCHZCHZ), 0.84—0.94 (t, 3H, CH3) ppm; 13C-NMR
(DMSO-d6): 6169.08 (C-1), 158.32 (C=N), 71.91 (C-4),
65.46 (CHZO), 49.06 (C-2), 29.84 (QHZCHZO), 28.29 (C-3),
18.35

(QHZCHZCHZO),

13.41

(CH3)

ppm;

Anal.

(C9H22Cl2N4O3.0.75 H2O. 0.25 C4H9OH) C, H, N, Cl.

5,859,295
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A)

EXAMPLE 17

n-Octyl L-2-amino-4-guanidinooxybutanoate (15)
L-canavanine (0.20 g, 1.13 mmol) Was heated in 5 mL of
11% HCl/anhydrous octanol (W/W) at 80° C. for 24 h. The
resulting mixture Was ?ltered. The solvent Was removed

under high vacuum With gentle heating at 50°—60° C. The
viscous residue Was dissolved in 1 mL of Water and the

resulting solution Was lyophiliZed. Aclear hygroscopic (0.04
g) residue Was obtained (10% yield); [ot]D23=+7.6°

(1)

10.5 (0.10 mol) of N,N‘-ethylenethiourea (98%) Was
suspended in 50 ml of EtOH (abs.). EtI (16.7 g, 0.11 mol)

(c=0.485, H2O); 1H-NMR (DMSO-dG): 68.80—9.60 (br s,
3H, NH,*), 7.80 (s, 5H, C(NH2)NH3+), 4.12420 (t,2H,
OCHZ), 3.92—4.00 (t, 1H, 2-CH), 3.35 (t, 2H, 4-CH2, overlap
With Water peak), 2.04—2.24 (m, 2H, 3-CH2), 1.56—1.66 (m,

2H, OCHZCHZ), 1.22—1.38 (m, 10H, OCH2CH2(CH2)5),
0.82—0.90 (t, 3H, CH3) ppm; 13C-NMR (DMSO-dG):
6169.10 (C-1), 158.33 (C=N), 71.91 (C-4), 65.72 (CHZO),
49.06 (C-2), 31.11, 28.47, 28.46, 28.31, 27.81, 25.07, 21.96
(C-3 and (QH2)6CH2O), 13.85 (CH3) ppm. Anal.
(C13H3ON4O3Cl2 0.95 H2O. 0.04 C8H17OH) C, H, N, Cl.

(2)

10

15

Was added into this suspended solution. The reaction mix
ture Was re?uxed for 2 hours. After cooling the solution to
RT, 50 ml of ethyl ether Was added and the mixture Was
cooled to 40° C. and stayed for 3 hours at 4° C. The mixture
Was ?ltered and the solid Was Washed With ethyl ether. Yield

21.2 g (82.5%) of
B)

20

Synthesis of Analogs of Canavanine
Scheme 1: Synthesis of D-2-amino-3-(guanidinooxy) pro

pionic acid (D-GOA)

25

H

O

N \ O 2N HCl

(2)

L

30

NH;

(3)

5.0 g (0.085 mol) of KOH Was dissolved in 20 ml of EtOH

(abs.) and 21.2 g (0.084 mol) of (2) Was added into this
solution. The mixture Was stirred for 30 min. at RT, and 100
ml of Water Was added. The mixture Was extracted With

5

O

NH

HO“
O/
H‘
NH;

CuO, HZNCN

2%

35

ZnClg, HZS

DCM (3><100 ml). The combined DCM solution Was Washed
With Water (3><200 ml) and dried over Na2SO4. Solvent Was
evaporated, to yield an oily residue of

6

C)
O
HO

NH;
,

o/

NR/

40

NHz

' NH;

4

(3)

45

Scheme 2: Synthesis of L-2-amino-4-(1-imidaZolidene
aminooxy) butanoic acid (L-ETCAV) and L-2-amino-4

[assym-NG, NG-dimethyl (guanidinooxy)]butanoic acid
(L-DMCAV)

(4)

6.9 g (0.3 mol) of Na (metal) Was dissolved in 100 ml of
EtOH (abs.) and the solution Was cooled to RT. Then the

O

H
N
0

HO

,'

\N

NH2
8
HO

N
H

CuO, ZnClZ, H25
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above oily residue of (3) Was added into the ethyl alcohol

1) Synthesis of N,N‘-ethylene canavanine

solution and the mixture Was re?uxed for 72 hours. The

5,859,295
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solution Was cooled to RT and 100 ml of Water Was added.

rated. The residue Was puri?ed by DoWex 50><8 (NH4+). The

The mixture Was extracted With DCM (3><100 ml.), dried
over Na2SO4. The solvent Was evaporated. The yield of (4)

product Was crystalliZed from ethanol (yield 30.3%).

3) Preparation of

Was 6.79 g (71.4%).

D)
NH;

10

L-Canaline

2

200 mg of dry L-canavanine Was dissolved in 50 ml of
MeOH (abs.). Anhydrous HCl Was introduced into the
solution for 10 min. Then the solution Was re?uxed for 1 h.

15

With bubbling of HCl (20 bubble per min.). The solvent Was
then evaporated. The residue Was recrystalliZed from methyl
alcohol and diethyl ether, dried under vacuum, to yield 270

mg (90%) of the methyl ester. 1H-NMR (D20 +TSP), 6:

2.2—2.3 (2H. m); 3.72 (3H, s); 3.95—4.05 (2H, m); 4.15—4.22

(1H,

4) Preparation of

20

NH
NH;

N,N'—ethylene—L-canaline

400 mg of dry L-canavanine Was dissolved in 60 ml of
EtOH (abs.). Anhydrous HCl Was introduced into the solu

536 mg (4 mmol) of canaline Was dissolved in 7 ml of
Water, and 954 mg (12 mmol) of CuO Was added. The
suspended solution Was boiled for 5 min, then stirred for 2
hours at 50° C. and for 20 hours at RT. The excess CuO Was

tion for 10 min. Then the solution Was re?uxed for 2 h. With
30

removed by ?ltration. The pH of the solution Was adjusted
to 9.2 With 1N NaOH. 1.04 g (8 mmol) of (4) Was added. The
mixture Was stirred for 90 hours at 45° C. Then H2S Was
bubbled into the mixture for 10 min. The CuS Was removed
by ?ltration. The solution Was evaporated. The residue Was
dissolved in 1 ml of Water. The products Were precipitated
from the solution using a mixture of ethanol and diethyl

2

25

bubbling of HCl (20 bubble per min.). The solvent Was then
evaporated. The residue Was recrystalliZed from methyl
alcohol and diethyl ether, dried under vacuum, to yield 510

mg (81%). 1H-NMR (DMSO-d6), 6: 1.19 (3H. t); 2.10—2.30

(2H, m); 3.85—3.95 (2H, m); 4.05—4.15 (1H, m); 4.17 (2H,
q); 7.75—7.85 (5H, broad).
35

5) Preparation of

ether (1:1). The solid Was puri?ed by crystalliZation from

ethanol (yield 32.3%).
2) Synthesis of N,N-dimethyl canavanine

40

0.490 g (1.77 mmol) of ethyl-L-canavanine ester (2HCl
45

salt) Was dissolved in 5% NaHCO3 (25 ml) and 25 ml of
acetonitrile Was added. 1.36 g (6 mmol) of di-t-butyl dicar
bonate (97%) Was added. The mixture Was stirred for tWo

days at RT. The acetonitrile Was evaporated, and 20 ml of
Water Was added. The aqueous solution Was acidi?ed by

using 10 citric acid, and extracted With DCM (3><30 ml). The
50

DCM solution Was Washed With Water (4><30 ml), dried over

NaZSO4 and evaporated. Yield of the N,N-diBOC derivative

0.57 g (79.3%). 1H-NMR (CDCl3), 6: 1.22 (3H, t); 1.40 (9H,

55

N,N'—dimethyl-L—canaline

s); 1.42 (9H, s); 1.95—2.05 (1H, m); 2.05—2.15 (1H, m);
3.82—3.90 (2H, m); 4.15 (2H, q); 4.35—4.40 (1H, m);
5.35_5.40 [1H, d (broad)]; 5974.03 (1H, broad).
6) Preparation of

536 mg (4 mmol) of canaline Was dissolved in 3 ml of
Water, and 954 mg (12 mmol) of CuO Was added. The
suspended solution Was boiled for 5 min. and stirred for tWo

60

hours at 50° C. and 20 hours at RT. The excess CuO Was

NH;

2

removed by ?ltration. The pH of the solution Was adjusted

to 9.2. ZnCl2(0.586 g, 4.31 mmol) and (CH3)2NCN (0.302
g, 4.31 mmol) Was dissolved in 4 ml of Water, and the
solution Was added to the reaction mixture. The mixture Was 65

stirred for 72 h. at 45° C. Then HZS Was bubbled into the
solution for 20 min. The mixture Was ?ltered and evapo

2.76 g (20 mmol) of sodium phosphate monobasic Was
dissolved in 20 ml of Water (the concentration is 1M). The
pH Was adjusted to 7.8 With 2N NaOH. 0.277 g (1 mmol,)
of ethyl-L-canavanine ester (2 HCl salt, MW: 277.11) Was
added into the buffer solution. Then 10 ml of ethyl alcohol

5,859,295
19

20
8) Preparation of

Was added together With 0.247 g (1.1 rnol, MW 218) of
t-butyl dicarbonate (97%). The solution Was stirred for 20
hours at RT. Then the ethyl alcohol Was evaporated and 20

||

ml of Water Was added. The aqueous solution Was extracted

With DCM (3><30 ml). The DCM solution Was Washed With
Water (3><20 ml), and dried over Na2SO4. The solvent Was
evaporated. Yield of the N-BOC derivative Was 0.26 g

(85%). 1H-NMR (CDCl3), 6: 1.26 (3H, t); 1.42 (9H, s);
1.95—2.10 (1H, rn); 2.10—2.05 (1H, rn); 3.85—3.95 (2H, In);
4.19 (2H, q); 4.35—4.45 (1H, rn); 5.30—5.40 (1H, broad).
7) Preparation of

/

NH;

2

10

NH;

NHZ
NaHCO3

O

>

CH3CH2OOC

NHZ

BenZoic acid (0.366
3 rnrnol) and
N-hydroxysuccinirnide (0.345 g, 3 rnrnol) Was dissolved in
10 ml. of CH3CN. Then DCC (0.618 g, 3 rnrnol) Was added.

-continued
40

0

H

HO —OSuc

The mixture Was stirred for 24 h at RT. The DCU Was ?ltered
out.

Ethyl-L-canavanine dichloride salt (1.02 g, 0.36 rnrnol)
Was dissolved in 10% NaHCO3 (30 ml). The solution Was
cooled to 40 C. and the above C6H5—CO—OSu (in 15 ml.
of CH3CN) Was added dropWise. The mixture Was stirred for

45
C

0

12 h. at 4° C. and 12 h. at RT. Most of the solvent Was
evaporated and 25 ml of Water Was added. The mixture Was

II
c —N

extracted With ethyl acetate (3><30 ml). The ethyl acetate
phase Was Washed With 5% NaHCO3 (1x20 ml.) and Water
(1><20 ml), and dried over NaZSO4 (3 days at 4° C. to

/ 1

\

NH;

%

C

//
O

precipitate DCU completely). The NaZSO4 Was ?ltered out
and the ethyl acetate Was evaporated. The residue Was

0

dissolved in 10 ml. of ethyl alcohol and 1 ml. of HCl (6N)

||

/

Was added. The ethyl alcohol Was evaporated and another 10

ml. of ethyl alcohol Was added and evaporated again. The
residue Was recrystallized from ethyl alcohol and diethyl
ether, and dried under vacuum. 1H-NMR (DMSO-dG), 67 :

8.90 (1H, d); 7.89 (2H, d); 7.65—7.80 (5H, broad); 7.42—7.60
(3H, rn); 4.55—4.65 (1H, In); 4.12 (2H, q); 3.89 (2H, t);
2.05—2.20 (1H, rn); 2.20—2.35 (1H, In); 1.19 (3H, t). 13C
NMR (DMSO-dG): 6: 171.87 (C=O); 167.06 (C=O);
158.36 (C=N); 133.67 (C—Ar); 131.90 (QH—Ar); 128.59
(QH—Ar); 127.60 (QH—Ar); 73.34 (O—QH2CH3); 61.02
(O—CH2CH2_); 49.70 (otQH); 28.88 ([3-CH2); 14.26 (
CH3). Calcd for C14H21N4O4Cl. 1A1 H2O: C:48.14; H: 6.18;

HOOC
60

65

NaOH (8.0 g, 0.2 rnol) Was dissolved in 400 ml. of a
mixture of Water and ethanol (1:1). After the solution Was

N: 16.04; Cl: 10.16. Found: C: 48.20; H: 6.21; N: 15.54; Cl:

cooled to RT, guanidine hydrochloride (9.5 g, 0.1 rnol) and

10.43.

di-t-butyl bicarbonate (Boc)2O Was added. The solution Was

5,859,295
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stirred for 24 hours at RT. The ethanol Was evaporated. The

13C-NMR (DMSO-d6): 6: 171.87 (C=O); 167.06 (C=O);
158.36 (C=N); 133.67 (C—Ar); 131.90 (QH—Ar); 128.59
(QH—Ar) 127.60 (QH—Ar); 73.34 (O—QH2CH3); 61.02
(O—CH2CH2—) 49.70 (or-CH); 28.88 ([3-CH2); 14.26
(CH3). Calcd for C14H21N4O4Cl. 1A1 H2O: C: 48.14, H: 6.18;

Water solution Was extracted With ethyl acetate (5><100 ml).
The ethyl acetate solution Was Washed With Water (2x20 ml),
dried (Na2SO4) and the solvent removed to yield 3.1 g of N-t

butyloxycarbonyl-guanidine [Boc—N=C(NH2)2], 78.0%.
1H-NMR(CDCl3): 61.43 (9H, s); 6.10—6.20 (4H, broad).

N: 16.04; Cl: 10.16. Found: C: 48.20; H: 6.21; N: 15.54; Cl:

13C-NMR (DMSO-d6): 6: 163.216 (C=O); 162.68 (C=N);
75.56 [—O—Q(CH3)3]; 28.23 (CH3).

10.43.

Further, the compounds of the present invention are useful

in pharmaceutical compositions for systemic administration

Boc-Glu(OH)-t-butyl (0.606 g, 2.0 mmol) Was dissolved

in DCM (20 ml.). N-hydroxysuccinimide (HO—Suc)

10

to humans and animals in unit dosage forms, such as tablets,

capsules, pills, poWders, granules, suppositories, sterile

(0.253, 2.2 mmol) Was added. The solution Was cooled to 00
C. DCC (0.453 g, 2.2 mmol) Was added. The solution Was
stirred for 2 hours at 0° C. and 20 hrs at RT. The DCU Was

parenteral solutions or suspensions, sterile non-parenteral
solutions or suspensions, oral solutions or suspensions,

?ltered out. The solvent Was evaporated. The residue Was
oil-in-Water or Water-in-oil emulsions and the like, contain
dissolved in 5 ml. of DCM and left to stand for 24 hours at 15 ing suitable quantities of an active ingredient.
For oral administration either solid or ?uid unit dosage
4° C. More DCU Was ?ltered out. The solvent Was evapo

rated again.
Boc—N=C(NH2)2 (0.477 g, 3 mmol) and TEA (0.648 g,

forms can be prepared. The compounds are useful in phar

5 mmol) Was dissolved in ethyl acetate (20 ml). The solution

With a carrier or vehicle in the composition of about 0.01 to

Was cooled to 0° C. Boc-Glu(OSu)-t-But in 10 ml. of ethyl

maceutical compositions (Wt %) of the active ingredient
20

acetate Was added. The mixture Was stirred for 2 hours at 0°

C. and 20 hours at RT. 20 ml of ethyl acetate Was added and

the solution Was Washed With 5% NaHCO3 (2><30 ml.),

Water (1><30 ml), 5% citric acid (2><30 ml) and Water (3><30
ml)m, dried over NaZSO4 and evaporated. The residue Was
recrystalliZed from ethyl acetate and hexanes. Yield 0.70 g,

25

1.48 mmol) Was added. The solution Was returned to RT and
stirred for 1 h. at RT. The solvent Was removed. 20 ml of
ethyl alcohol Was added and the solution evaporated and
dried under vacuum. The residue Was precipitated With ethyl

dicalciumphosphate, magnesium aluminum silicate, magne
sium stearate, calcium sulfate, starch, talc, lactose, acacia,
methyl cellulose and functionally similar materials such as
pharmaceutical excipients or carriers. A sustained release
formulation may optionally be used. Capsules may be for

78.8%. 1H-NMR(CDCl3): 61.44 (9H, s); 1.47(9H, s); 1.48
(9H, s); 1.86—2.00 (1H, m); 2.10—2.24 (1H, m);2.34—2.42
(2H, m); 4.16—4.25 (1H,
Ethyl acetate (20 ml) and 36% HCl (10 ml) Was mixed
and cooled to 0° C. Boc-Glu[N=C(NH2)2]-t-But (0.66 g,

99% and preferably about 5 to 15%.
Either ?uid or solid unit dosage forms can be readily
prepared for oral administration. For example, the com
pounds can be mixed With conventional ingredients such as

mulated by mixing the compound With a pharmaceutical
30

diluent Which is inert and inserting this mixture into a hard

gelatin capsule having the appropriate siZe. If soft capsules
are desired a slurry of the compound With an acceptable

(D20): 6: 2.17—2.27 (2H, m); 2.72—2.82 (2H, m); 3.93—4.00

vegetable, light petroleum, or other inert oil can be encap
sulated by machine into a gelatin capsule.
Suspensions, syrups and elixirs may be used for oral
administration of ?uid unit dosage forms. A?uid preparation
including oil may be used for oil soluble forms. Avegetable

(1H,

oil such as corn oil, peanut oil or safflower oil, for example,

35

alcohol and diethyl ether, and dried under vacuum. 1H-NMR

13C-NMR(D2O): 6:177.90 (C=O); 175.50

(C=O); 157.30 (C=N); 55.66 ((XQH); 35.27 (Y-QHZ); 27.13
([3-CH2), Calcd for C6H14O3N4Cl2O: C: 26.68; H: 5.60; N:
20.74; Cl: 26.25. Found: C: 26.71; H: 5.60; N: 20.77; Cl:

40

together With ?avoring agents, sWeeteners and any
preservatives, produces an acceptable ?uid preparation. A
surfactant may be added to Water to form a syrup for ?uid

26.17.

unit dosages. Hydro-alcoholic pharmaceutical preparations

9) Ethyl N°‘-benZoyl-L-canavanine ester

may be used having an acceptable sWeetener such as sugar,
saccharine or a biological sWeetener and a ?avoring agent in
the form of an elixir.

BenZoic acid (0.366 g., 3 mmol) and
N-hydroxysuccinimide (0.345 g, 3 mmol) Was dissolved in
10 ml. of CH3CN. DCC (0.618 g, 3 mmol) Was then added.

45

Pharmaceutical compositions for parenteral administra
tion can also be obtained using techniques standard in the art
as set forth in Remington ’s Pharmaceutical Sciences, 18th

The mixture Was stirred for 24 h. at RT. The DCU Was

?ltered off.

Ethyl-L-canavanine ester dichloride salt (1.02 g, 0.36
mmol) Was dissolved in 10% NaHCO3 (30 ml). The solution

Ed., 1989, Mack Publishing Company, incorporated herein
50

Accordingly, compositions suitable for administration are
particularly included Within the invention. Parenteral solu

Was cooled to 4° C. and the above C6H5—CO—OSu (in 15
ml. of CH3CN) Was added dropWise. The mixture Was
stirred for 12 h. at 4° C. and 12 h. at RT. Most of the solvent

tions or suspensions may be administered. If desired, a more

concentrated sloW release form may be administered.

Was evaporated, and 25 ml of Water Was added. The mixture

Was extracted With ethyl acetate (3><30 ml). The ethyl acetate
phase Was Washed With 5% NaHCO3 (1><20 ml.) and Water
(1><20 ml.), and dried over NaZSO4 (3 days at 4° C. to
precipitate the DCU completely). The NaZSO4 Was ?ltered

55

Accordingly, incorporation of the active compounds in a
sloW release matrix may be implemented for administering

transdermally. The compounds may preferably be adminis
tered at about 1 to 20% of the composition and more

preferably about 5 to 15% Wt % of the active ingredient in

off and the ethyl acetate Was evaporated. The residue Was

dissolved in 10 ml. of ethyl alcohol, and 1 ml. of HCl (6N)

by reference it its entirety.

60

the vehicle or carrier.

Was added. The ethyl alcohol Was evaporated and another 10
ml. of ethyl alcohol Was added and the solution evaporated

The above and other drugs can be present in the reservoir
alone or in combination form With pharmaceutical carriers.

again. The residue Was recrystalliZed from ethyl alcohol and
diethyl ether, and dried under vacuum. 1H-NMR (DMSO

this invention are the art knoWn carriers that do not

d6), 6: 8.90 (1H, d); 7.89 (2H, d); 7.65—7.80 (5H, broad);
7.42—7.60 (3H, m); 4.55—4.65 (1H, m); 4.12 (2H, q); 3.89
(2H, t); 2.05—2.20 (1H, m); 2.20—2.35 (1H, m); 1.19 (3H, t).

The pharmaceutical carriers acceptable for the purpose of
65

adversely affect the drug, the host, or the material compris
ing the drug delivery device. Suitable pharmaceutical car
riers include sterile Water; saline, dextrose; dextrose in Water

5,859,295
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23
or saline; condensation products of castor oil and ethylene
oxide combining about 30 to about 35 moles of ethylene
oxide per mole of castor oil; liquid acid; loWer alkanols; oils

30. Rosenthal G. A. Phytochemistry 30:1055, 1991.
31. Rosenthal G. A. et al. J Biol Chem 264:13693, 1989.
32. Rosenthal G. A. et al. J Biol Chem 264:9768, 1989.
33. Rosenthal G. A. & Dahlman D. L. J Biol Chem

such as corn oil; peanut oil, sesame oil and the like, With
emulsi?ers such as mono- or di-glyceride of a fatty acid, or

266:15684, 1991.

a phosphatide, e.g., lecithin, and the like; glycols; polyalky
lene glycols; aqueous media in the presence of a suspending

34. Thomas D. A. et al. Cancer Res 46:2898, 1986.

agent, for example, sodium carboxymethylcellulose; sodium
alginate; poly(vinylpyrolidone); and the like, alone, or With
suitable dispensing agents such as lecithin; polyoxyethylene

36. Thomas D. A. & Rosenthal G. A. Toxicol & Appl Pharm

stearate; and the like. The carrier may also contain adjuvants

35. Rosenthal G. A. Unpublished experimental results.
10

such as preserving, stabiliZing, Wetting, emulsifying agents

Acids: Biological, Biochemical, and Toxicological

and the like together With the penetration enhancer of this
invention.
The effective dosage for mammals may vary due to such
factors as age, Weight, activity level or condition of the

Properties, Academic Press: San Diego, 1982; p. 273.
(38) Rosenthal, G. A. The Protective Action of a Higher
15

subject being treated. Typically, an effective dosage of a
compound according to the present invention is about 0.1 to
50 mg per kilogram of the subject’s Weight administered per

day. Preferably about 25 to 50 mg per kilogram body Weight
is administered per day. The required dose is less When
administered parenterally, preferably about 25—30 mg per

20

kilogram of body Weight per day may be administered

intramuscularly.
25

1. Douglass H. O., Tepper J ., Leichman L. Neoplasms of the
bile duct and pancreas, in: Cancer Medicine, Holland J.
F., Frei et al. eds. Third edition: Lea and Febiger, 1993.
. Wynder E. L. Cancer Res. 35:2228, 1975.
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(42) Rosenthal, G. A.; Dickey, K. M.; Gilding, H.: Crooks,
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illustrate some embodiments of the present invention With
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skill in the art that various modi?cations and variations may
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be made to the composition and method of the present
invention Without departing from the spirit or scope of the
invention. All patents and publications cited herein are

19. Abe M & Takahashi M. Int J Radiat Oncol Biol Phys

7:863, 1981.
20. Moertel C. G. et al. Surg 85:509, 1979.
21. Evans R. M. et al. Cancer Res 41:3288, 1981.
22. Keyomarski K. & Moran R. G. Cancer Res 46:5529,
1985.
23. CroWn J et al. J Clin Oncol 9:1682, 1991.
24. Ardalan B & Singh G. J Clin Oncol 6:1053, 1988.
25. Nagourney R. A. et al. Proc Am Soc Clin Oncol 13:636,
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incorporated by reference in their entireties.
We claim:

1. Canavanine analog compound having a formula
selected from the group consisting of: Formula 1
55
R

1994.
26. Rosenthal G. A. Plant Nonprotein Amino and Imino

Acids, Biological, Biochemical, and Toxicological
Properties, Academic Press, San Diego, 1982.
27. Rosenthal G. A. Q Rev Biol 52, 155, 1977.
28. Rosenthal G. A. In: Insecticides: Mechanism of Action
and Resistance D. Otto & B. Weber, eds. Intercept Ltd.,

Andover, England, 1982.
29. Rosenthal G. A. In: Frontiers and New Horizons in

Amino Acid Research, K. Takai, ed. Elsevier, NeW York,
1992.
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R5

Wherein

R3 is H2; —(CH3)2; or H-Boc
R4 is —CH2CH3; or —CH3
R5 is H; H-Boc; or

5,859,295
25

26
L-Canavanine Esters;

and

Methyl L-2-amino—4-guanidinooxybutanoate;
Ethyl L-2-amino—4-guanidinooxybutanoate;
Isopropyl L-2-amino-4-guanidinooxybutanoate;
n-Propyl L-2-amino-4-guanidinooxybutanoate;
n-Butyl L-2-amino-4-guanidinooxybutanoate;
2. Acanavanine analog compound of claim 1 wherein said
compound is selected from the group consisting of

D-2- mino-3-(aminooxy)propionic acid dihydrochlo

10

ride;

n-Octyl-4-guanidinooxybutanoate and mixtures thereof.
11. A method of treating pancreatic cancer according to
claim 10 Wherein said composition further comprises
5-?uorouracil.
12. A method of treating pancreatic cancer according to

D—2-Amino-3-(guanidinooxy)propionic acid;
L-2-Amino-4- [assym-NG, NG-dimethyl (guanidinooxy)]

claim 10, Wherein said composition further comprises a

compound selected from the group consisting of (S)

butanoic acid;
L-Canavanine Esters;

15

2-aminoethyl-L-cysteine, L-2-aZetidine carboxylic acid,

L-selenomethionine, L-3-[N-hydroxy-4-oxypyridyl]—2

Methyl L-2-amino—4-guanidinooxybutanoate;
Ethyl L-2-amino—4-guanidinooxybutanoate;
Isopropyl L-2-amino-4-guanidinooxybutanoate;
n-Propyl L-2-amino—4-guanidinooxybutanoate;
n-Butyl L-2-amino-4-guanidinooxybutanoate;

amino-propionic acid and mixtures thereof.
13. A method of treating pancreatic cancer according to
claim 10, Wherein said pharmaceutically effective amount is
about 25 to 50 mg per kilogram body Weight a day.
14. Canavanine analog compound having a formula

n-Octyl-4-guanidinooxybutanoate, and mixtures thereof.
3. A canavanine analog compound of claim 2, Wherein

NR3R4

said L-Canavanine Esters are selected from the group con

sisting of methyl, ethyl, isopropyl and n-propyl esters of

25

R1OOC

CH2— (cH2),,—o —N =c

i:

L-canavanine.

4. A pharmaceutical composition comprising a pharma

RZHN

ceutically effective amount of a compound according to
claim 1 and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition according to claim 4
Wherein said compound is selected from the group consist

Formula 4

NHR5
H

Wherein

ing of
D-2- mino-3-(aminooxy)propionic acid dihydrochlo

ride;

D—2-Amino-3-(guanidinooxy)propionic acid;
L-2-Amino-4- [assym-NG, NG-dimethyl (guanidinooxy)]
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butanoic acid;
L-Canavanine Esters;

Methyl L-2-amino—4-guanidinooxybutanoate;
Ethyl L-2-amino—4-guanidinooxybutanoate;
Isopropyl L-2-amino-4-guanidinooxybutanoate;
n-Propyl L-2-amino—4-guanidinooxybutanoate;
n-Butyl L-2-amino-4-guanidinooxybutanoate;
n-Octyl-4-guanidinooxybutanoate and mixtures thereof.
6. A pharmaceutical composition according to claim 4
Wherein said composition further comprises 5-?uorouracil.
7. A pharmaceutical composition according to claim 4
Wherein said composition further comprises a compound
selected from the group consisting of (S) -2-aminoethyl-L

cysteine,

L-2-aZetidine

carboxylic

45

acid,

O

“

L-selenomethionine, L-3—[N-hydroxy-4-oxypyridyl]—2
aminopropionic acid and mixtures thereof.
8. A method of treating cancerous tumor comprising the
steps of administering a pharmaceutically effective amount

55
Formula 3

of a compound according to claim 1 to a patient With cancer.

9. A method of claim 8, Wherein said cancer is pancreatic
cancer.

10. A method of treating pancreatic cancer according to
claim 1 Wherein said compound is selected from the group

consisting of
D-2- mino-3-(aminooxy)propionic acid dihydrochlo

ride;

D—2-Amino-3-(guanidinooxy)propionic acid;
L-2-Amino-4- [assym-NG, NG-dimethyl (guanidinooxy)]
butanoic acid;

Formula 2

H2
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